TY - JOUR
T1 - Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
AU - Cortinovis, Diego
AU - Bidoli, Paolo
AU - Cullurà, Daniela
AU - Lorusso, Vito
AU - Ardizzoia, Antonio
AU - Amoroso, Vito
AU - Bandera, Mauro
AU - Aitini, Enrico
AU - Fusi, Alberto
AU - Zilembo, Nicoletta
AU - Radula, Daniela
AU - Bajetta, Emilio
PY - 2008/4
Y1 - 2008/4
N2 - INTRODUCTION: The ability of doublet therapy in the second-line setting in patients with platinum-refractory non-small cell lung cancer (NSCLC) has not yet been proven. In this setting, docetaxel (D) has shown efficacy and irinotecan (I) has only recently been introduced. This study was initiated to explore the activity and tolerability of three D + I regimens in platinum pretreated NSCLC patients. METHODS: From March 2003 to June 2006, 65 patients (age range, 39-71 years; 83% male) with relapsed stage III/IV NSCLC were randomly assigned to receive either I 160 mg/m plus D 60 mg/m on day 1 every 21 days (arm A), I 80 mg/m on days 1,8 plus D 60 mg/m on day 1 every 21 days (arm B), or I 60 mg/m plus D 30 mg/m on days 1, 8, 15, and 22 every 42 days (arm C), for a maximum of 18 weeks. RESULTS: Per protocol analysis (47 of 65) overall response rates were 5.6% (A), 6.7% (B), and 7.1% (C). Median times to progression were 3.4, 4.0, and 4.3 months, respectively. Overall survival was 8.9 (A), 8.3 (B), and 9.4 (C) months. G3/4 neutropenia was more frequent in arms A (42%) and B (55%) whereas G3/4 nonhematologic toxicity was similarly prevalent in all arms, although diarrhea occurred in 47% of arm C patients. CONCLUSIONS: Single-agent treatment with D or the multitarget antifolate pemetrexed or erlotinib remain the best choices and investigational studies, following first-line therapy, are required.
AB - INTRODUCTION: The ability of doublet therapy in the second-line setting in patients with platinum-refractory non-small cell lung cancer (NSCLC) has not yet been proven. In this setting, docetaxel (D) has shown efficacy and irinotecan (I) has only recently been introduced. This study was initiated to explore the activity and tolerability of three D + I regimens in platinum pretreated NSCLC patients. METHODS: From March 2003 to June 2006, 65 patients (age range, 39-71 years; 83% male) with relapsed stage III/IV NSCLC were randomly assigned to receive either I 160 mg/m plus D 60 mg/m on day 1 every 21 days (arm A), I 80 mg/m on days 1,8 plus D 60 mg/m on day 1 every 21 days (arm B), or I 60 mg/m plus D 30 mg/m on days 1, 8, 15, and 22 every 42 days (arm C), for a maximum of 18 weeks. RESULTS: Per protocol analysis (47 of 65) overall response rates were 5.6% (A), 6.7% (B), and 7.1% (C). Median times to progression were 3.4, 4.0, and 4.3 months, respectively. Overall survival was 8.9 (A), 8.3 (B), and 9.4 (C) months. G3/4 neutropenia was more frequent in arms A (42%) and B (55%) whereas G3/4 nonhematologic toxicity was similarly prevalent in all arms, although diarrhea occurred in 47% of arm C patients. CONCLUSIONS: Single-agent treatment with D or the multitarget antifolate pemetrexed or erlotinib remain the best choices and investigational studies, following first-line therapy, are required.
KW - Docetaxel
KW - Irinotecan
KW - Non-small cell lung cancer
KW - Phase II
KW - Randomized trial
KW - Second-line chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=41749102428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41749102428&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e318168f780
DO - 10.1097/JTO.0b013e318168f780
M3 - Article
C2 - 18379360
AN - SCOPUS:41749102428
VL - 3
SP - 405
EP - 411
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 4
ER -